In a randomised single blind trial the Chinese herbs Shuang Huang Lian were evaluated for the treatment of acute bronchiolitis. Children with acute bronchiolitis and serological evidence of recent respiratory syncytial virus infection were studied in a tertiary hospital in Harbin, China. The 96 children were randomised into three treatment groups: herbs, herbs with antibiotics, and antibiotics alone. The herbs were prepared by the medical school pharmacy and administered daily by intravenous infusion for seven days. The main outcomes, assessed blindly, were symptomatic improvement in cough, fever, wheezing, chest signs, and duration of stay in hospital.
Acute bronchiolitis is the most common serious respiratory infection in infancy, affecting one in 50 infants annually in industrialised countries.' The respiratory syncytial virus is responsible for over 80% of hospital admissions, with a peak incidence during the winter months.
Respiratory syncytial virus bronchiolitis is also an important problem in the developing world. A group of studies from 10 developing countries on the epidemiology of acute respiratory infections reported that the children studied spent an average of 22-40% of observed weeks with signs of acute respiratory infection, and had incidence rates for lower respiratory tract disease ranging from 0-2 to 8-1 new episodes per 100 child weeks at risk, with the highest incidence in children less than 18 months of age. 2 Although death rates for bacterial pneumonia are more than 50 times higher than for viral lower respiratory tract infections, the estimated number of deaths is only about 2 -7 times higher for bacterial pneumonia. 3 Respiratory syncytial virus is the most often identified agent in these studies, accounting for 15-20% of all viral pathogens, though mixed infections also occur."
Oxygen and nursing care are the mainstays of hospital management of acute bronchiolitis.
There is no evidence that bronchodilators, corticosteroids, or antibiotics improve the course of the illness. Tribavirin (ribavirin) administered by aerosol has been shown to be effective,7 but its administration is complex and its role in treatment of patients outside an intensive care unit is still unclear. Thus, a new effective treatment for acute bronchiolitis could offer considerable benefits.
Traditional Odds ratios and 95% confidence intervals were calculated using the computer program Epi Info version 5. The geometric mean durations of signs and symptoms with 95% confidence intervals were calculated after log transformation.
Results
On admission, all 96 children in the study group had coughing, 91% were wheezing, 86% had chest crackles, 80% had chest wheezes, and 53% had fever. Using a modified severity score,'5 35 patients had mild disease, 44 moderate, and 17 severe. None of the patients required artificial ventilation, and there were no deaths. The median age of patients was 12 months; 22 were 0-6 months and 59 (61%) less than 12 months of age. As expected with respiratory syncytial virus infection in a hospital setting, there was a 2:1 male predominance and striking winter season- antibiotics) (antibiotics)
Cough (n=%)
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Any sign or symptom (n=%)
6-4 (5-6 to 7-3) 6-0 (50 to 7-1) 8-6 (7-5 to 9-8)
Hospital stay (n=9%)
7-8 (7-0 to 8-6) 7-0 (6-3 to 7-8) 9-8 (8-8 to p<001 for groups AB combined v C, except for fever. Note: the discrepancy with the abstract data is due to non-geometric mean data.
ality. There were no important differences between treatment groups on entry into the trial (table 1) . The course of the illness was significantly shorter in groups A and B than in group C (table  2) . No significant differences were detected between groups A and B, so they have been combined into the 'herbal' group with group C as 'non-herbal'. The mean duration of symptoms for herbal treatment was 6-2 (confidence interval 5-6 to 6 9) days compared with (confidence interval 7 5-9 8) days in the non-herbal group. Furthermore, there were more children with an improvement in symptoms within two days of starting herbal treatment, and fewer with symptoms persisting for one week than in the nonherbal group (table 3 14 adults after treatment with Shuang Huang Lian."7 After administration by mouth, peak serum concentrations of 4-6 jig/ml were reached at six hours, and levels of around 2 [.g/ml for each component persisted for two to eight hours after intravenous infusion. The lethal dose (LD50) of Shuang Huang Lian injection from animal studies is 56 1 (7-1) ml/kg.
There are some features of respiratory syncytial virus infection in these Chinese children which differ from the typical disease seen in paediatric wards in Western countries. We believe that these differences are real and not just related to patient selection or diagnostic criteria. At the First Hospital in Harbin, bronchiolitis is a less acute illness which affects a slightly older age group, and patients present later to hospital and have a more prolonged disease course. Thus, our non-herbal group had symptoms for a mean of 15 days, including six days before admission. A Beijing study found respiratory syncytial virus in 47 (13%) of 364 acute respiratory admissions in children under 5 Finally, this was not a placebo controlled trial. Placebos were not considered acceptable in this cultural context, so intravenous antibiotic administration was used instead of a placebo in the non-herbal group and also in one of the groups treated with Shuang Huang Lian. Although ward staff and parents were not specifically blind to the study, the protocol for intravenous antibiotic treatment was similar to the herbal administration as once daily intravenous administration. The use of antibiotics as placebo could introduce a potential bias, as two studies have found antibiotics to be possibly detrimental in respiratory syncytial virus bronchiolitis.2021 Our study design with three groups enables us to exclude this, however, as we found no differences between the groups treated with herbs and antibiotics (group B) and herbal only group (group A) (table 2).
In conclusion, the results of this study support the clinical experience with Shuang Huang Lian in the treatment acute bronchiolitis in China and show that it is safe and shortens the clinical course of the illness. We believe that the reductions in duration of symptoms in the patients treated with Shuang Huang Lian (tables 2 and 3) are clinically significant. Although the administration of Shuang Huang Lian intravenously in this study indicates its pharmacological potency, this method of treatment for seven days would limit its usefulness in a Western context where admission to hospital for bronchiolitis may last only a few days. Consequently, one of us (Kong) is currently studying its administration as a nebulised solution, and preliminary results from Beijing Children's Hospital suggest that it is equally effective by this route. We believe that this warrants further study.
